Managing FCS is notoriously difficult. With standard lipid-lowering therapies often failing, strict diet has historically been the only tool. In this CME program, Dr. Shapiro reviews the pathophysiology and strategies to reduce pancreatitis risk. Watch the full video ➡️ https://www.facebook.com/watch/live/?ref=watch_permalink&v=1171021224648318 #CME | Medscape

1.9K views | Oral TKI or IV ADC for HER2+ NSCLC? The first oral medication for this disease, Zongertinib, is now approved, joining established IV therapies like Trastuzumab deruxtecan. Our experts discuss how to choose ▶️ https://www.facebook.com/events/566988496426095 #Oncology #CME | Medscape | Facebook

Reframing Heart Failure Care: Amplifying Patient Voices in the Evolving Treatment Landscape | Medscape

Acute Hepatic Porphyria: Bridging Gaps for Better Diagnosis and Management | Medscape

Do you treat patients with high triglycerides? Join a social media livestream exploring recent advances in severe hypertriglyceridemia and familial chylomicronemia syndrome (FCS) and apolipoprotein C3 (APOC3) inhibitors, led by renowned lipid expert Dr Michael Shapiro. Targeted to practicing physicians, this session will review pathophysiology and diagnostic pearls to distinguish FCS from multifactorial hypertriglyceridemia, summarize the latest clinical-trial and real-world evidence for APOC3-t